Author pages are created from data sourced from our academic publisher partnerships and public sources.
TP53 Mutational signature for aristolochic acid: an environmental carcinogen
- M. Moriya, N. Slade, +7 authors A. Grollman
- Biology, Medicine
- International journal of cancer
- 15 September 2011
This study was designed to establish the TP53 mutational spectrum of aristolochic acid (AA), examined in the context of endemic (Balkan) nephropathy, an environmental disease associated with… Expand
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations
The TP53 mutation profile in chronic lymphocytic leukemia (CLL) and the correlation of TP53 mutations with allele status or associated molecular genetics are currently unknown. We performed a large… Expand
Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling
- S. Chiaretti, S. Tavolaro, +15 authors R. Foà
- Biology, Medicine
- Genes, chromosomes & cancer
- 1 April 2011
Given that TP53 alterations predict prognosis and response to therapy in chronic lymphocytic leukemia (CLL), screening for TP53 mutations has an increasing role in patient management. TP53 direct… Expand
Living arrangements, patrilineality and sources of support among elderly Vietnamese.
- S. Truong, T. C. Bui, D. Goodkind, J. Knodel
- Medicine, Geography
- Asia-Pacific population journal
- 1 December 1997
This study examined social support for the elderly in Ho Chi Minh (HCM) City and Hanoi, Viet Nam, in 1996. The sample included the main towns and provinces surrounding the cities. Two major… Expand
Strong p53 Expression Is an Independent Predictor of Outcome in De Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Either CHOP or CHOP-R.
Background: The addition of rituximab to CHOP (CHOP-R) chemotherapy has resulted in an improved outcome for patients with DLBCL and has recently been shown to diminish the prognostic impact of two… Expand
TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.
Abstract 1267 Poster Board I-289 The international multicenter randomized CLL8 trial evaluated 1 st line treatment with FC or FCR in 817 CLL patients. Analysis of TP53 mutation status by a… Expand
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
In chronic lymphocytic leukemia (CLL) patients, disruptions of the TP53 tumor suppressor pathway by 17p13 deletion (del17p), somatic TP53 mutations, or downregulation of microRNA-34a have been… Expand
TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods
TP53 gene defects represent a strong adverse prognostic factor for patient survival and treatment resistance in chronic lymphocytic leukemia (CLL). Although various methods for TP53 mutation analysis… Expand
TP53 abnormalities in chronic lymphocytic leukemia exhibit a disease specific profile: meta-analysis of 270 mutations.
TP53 mutations have been shown to occur in 5–40% of CLL patients depending on the clinical background (early stage/refractory disease). They are associated with a poor response to standard… Expand
Clinical Impact of TP53 Gene Mutations in Diffuse Large B-Cell Lymphoma (DLBCL): An International DLBCL Rituxan-CHOP Consortium Program Study.
Abstract 967 Mutations of the TP53 tumor suppressor gene are associated with a poor clinical outcome in DLBCL patients treated with CHOP. The impact of TP53 mutations on clinical outcome of DLBCL… Expand